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Abstract
Vitamin  D3  (VD3) plays an important role in the ovary and its deficiency is associated with ovarian pathologies, including 
polycystic ovary syndrome (PCOS). However, there is no data related to  VD3 metabolism in the ovary during PCOS. Herein, 
we investigated differences in the expression of  VD3 receptor (VDR) and key  VD3 metabolic enzymes, 1α-hydroxylase 
(CYP27B1) and 24-hydroxylase (CYP24A1), in the ovary and periovarian adipose tissue (POAT) of control (proestrus and 
diestrus) and PCOS induced by letrozole rats. Vdr, Cyp27b1 and Cyp24a1 mRNA expression was determined, their protein 
abundance was examined and immunolocalized. Furthermore,  VD3 metabolite concentrations in plasma (25OHD) and tissues 
(ovary and POAT; 1,25(OH)2D3), and plasma calcium level were determined. 25OHD concentration decreased markedly in 
letrozole-treated rats in comparison with controls, whereas calcium concentration did not vary among the examined groups. 
The amount of 1,25(OH)2D3 decreased in both ovary and POAT of PCOS rats. In the ovary, we found decreased Cyp27b1 
and increased Vdr mRNA expression in letrozole-treated and diestrus control group. Corresponding protein abundances were 
down-regulated and up-regulated, respectively but only following letrozole treatment. In POAT, only Cyp27b1 transcript 
level and CYP27B1 protein abundance were decreased in letrozole-treated rats. VDR was immunolocalized in healthy and 
cystic follicles, while CYP27B1 and CYP24A1 were found exclusively in healthy ones. Concluding, our results provide the 
first evidence of disrupted  VD3 metabolism in the ovary and POAT of PCOS rats. The reduced 1,25(OH)2D3 concentration 
in those tissues suggests their contribution to  VD3 deficiency observed in PCOS and might implicate in PCOS pathogenesis.
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Introduction
It is widely accepted that vitamin  D3  (VD3) regulates cal-
cium and phosphorus homeostasis to ensure bone health 
(DeLuca 2004). However, due to the broad distribution of 
 VD3 receptor (VDR) in the organism,  VD3 effects extend 
to various tissues, including female reproductive organs. 
Recent studies also reveal that  VD3 insufficiency/deficiency 
associates with many reproductive disorders, such as endo-
metriosis, uterine fibroids, premature ovarian failure, ovarian 
cancer and polycystic ovarian syndrome (PCOS) (Dabrowski 
et al. 2015; Muscogiuri et al. 2017).
In humans and animals, the main source of circulating 
active  VD3 is its endogenous synthesis in the skin upon 
ultraviolet-B irradiation. In keratinocytes, 7-dehydrocho-
lesterol is converted to previtamin  D3, which is metabolized 
in the liver by 25-hydroxylases (e.g. CYP2R1, CYP27A1) 
to  25OHD3, and further in the kidney by 1α-hydroxylase 
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(CYP27B1) to the bioactive hormone 1,25(OH)2D3. Both 
1,25(OH)2D3 and  25OHD3 are inactivated by a mitochon-
drial 24-hydroxylase (CYP24A1) (Bikle 2014). To date, the 
ovary has been identified as an extrarenal site of CYP27B1 
expression and VDR is abundant in ovarian cells, suggest-
ing local  VD3 metabolism and action within the mammalian 
ovary (Herian et al. 2018; Xu et al. 2018). Indeed, there are 
numerous reports of positive  VD3 effects on folliculogenesis 
and steroidogenesis. In details,  VD3 was shown to increase 
the synthesis of anti-Müllerian hormone (AMH), maintain-
ing the ovarian reserve (Irani and Merhi 2014). In addition, 
Xu et al. (2018) reported a survival and development of pre-
antral and antral follicles in rhesus macaque following  VD3 
exposure in vitro. Moreover,  VD3 was found to stimulate 
progesterone and 17β-estradiol secretion by human granu-
losa cells (Parikh et al. 2010; Merhi et al. 2014). On the 
other hand, hypovitaminosis  D3 has been linked to several 
ovarian pathologies such as PCOS (He et al. 2015).
PCOS is a common disorder affecting women of repro-
ductive age (Fauser et al. 2012). In general, two criteria, 
such as oligoovulation/anovulation, hyperandrogenism and 
polycystic ovaries on ultrasound, must be met for PCOS 
diagnosis (Azziz et al. 2006). However, its phenotype is 
accompanied by a much wider range of reproductive (ovu-
latory dysfunction, polycystic ovarian morphology, infertil-
ity), endocrine (hyperandrogenism, disturbed gonadotropins 
level) and metabolic (glucose metabolism, insulin sensitiv-
ity, lipid profile) features (Fauser et al. 2012; Krul-Poel 
et al. 2018). Recent clinical and experimental studies have 
reported that  VD3 deficiency among women contributes to 
various disturbances associated with PCOS (Muscogiuri 
et al. 2017). To our knowledge, low serum  VD3 status causes 
dysregulation in calcium metabolism that may inhibit fol-
licle maturation and ovulation in women with PCOS (Thys-
Jacobs et al. 1999). The decreased  VD3 level also reduces the 
activity and expression of aromatase, which impairs conver-
sion of androgens to estrogens. In turn, increased androgen 
concentration blocks follicular maturation before ovulation 
and leads to ovarian cyst appearance (Lorenzen et al. 2017). 
Furthermore,  VD3 deficiency is significantly associated with 
a higher insulin resistance and a lower level of high-density 
lipoproteins in PCOS patients (Krul-Poel et al. 2018). By 
this time,  VD3 supplementation has been shown to improve 
menstrual regularity and ovulatory dysfunction as well as 
decrease serum androgens level and increase insulin sensi-
tivity in women with PCOS (Karadağ et al. 2018; Shojaeian 
et al. 2019). However, information about local ovarian  VD3 
metabolism in PCOS is still lacking. In the present study, we 
hypothesize that the  VD3 metabolic system differs between 
normal and polycystic ovaries.
This research aimed to determine whether  VD3 metabolic 
homeostasis is altered in the ovary and surrounding perio-
varian adipose tissue (POAT) of rats with PCOS induced by 
aromatase inhibitor letrozole (Kafali et al. 2004). To meet 
this goal we examined: (1) plasma 25OHD and calcium 
concentrations in control and PCOS rats, (2) 1,25(OH)2D3 
concentration in ovarian and POAT homogenates, (3) Vdr, 
Cyp7b1 and Cyp24a1 mRNA expression, and (4) VDR, 
CYP27B1 and CYP24A1 proteins abundance, and (5) 
immunolocalization in the ovary and POAT obtained from 
control and PCOS rats.
Materials and methods
Animals
Six-week-old female Wistar rats (mean body weight (BW) 
at the beginning of the experiment 191.375 ± 7.87 g) were 
purchased from Faculty of Pharmacy Jagiellonian Univer-
sity Medical College (Krakow, Poland) and Mossakowski 
Medical Research Centre Polish Academy of Sciences (War-
saw, Poland). Animals were housed in controlled conditions 
of temperature, humidity and light (12 h light: 12 h dark 
cycle) with ad libitum availability of food and water. Rats 
were allowed to acclimatize for one week before treatment. 
All experimental protocols listed herein were approved by 
the Local Animal Ethical Committee, Poland (permit no. 
277/2019).
PCOS was induced in rats by administration of nonsteroi-
dal aromatase inhibitor letrozole (Sigma-Aldrich, St. Louis, 
MO, USA) (Kafali et al. 2004; Kalamon et al. 2020). For 
PCOS induction, 48 rats were randomly assigned into the 
control (n = 32) and letrozole-treated (n = 16) groups. A 
daily treatment regime of 21 days included oral adminis-
tration through gavage of either 2% (v/v) dimethyl sulfox-
ide (DMSO; Sigma-Aldrich) in rapeseed oil (1 ml/kg BW) 
in the first group or letrozole (1 mg/kg BW) dissolved in 
2% DMSO in rapeseed oil in the second group. Rats were 
weighed daily for 21 consecutive days of the experiment. 
After 21 days of treatment, BW, estrous cyclicity, plasma 
testosterone (T) and 17β-estradiol  (E2) levels as well as ovar-
ian histology were analyzed to verify the development of 
PCOS.
Assessment of estrous cyclicity
Estrous cyclicity was monitored by microscope analysis of 
vaginal epithelial cell smears. Smears were stained using 
May-Grundwald and Giemsa procedure (Kolchem, Lodz, 
Poland). Proestrus was characterized by the presence of pre-
dominantly nucleated and some cornified epithelial cells, 
estrus as mostly cornified cells, metestrus as some corni-
fied epithelial cells and primarily leukocytes and diestrus as 
primarily leukocytes (Marcondes et al. 2002). As a control 
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groups, animals from proestrus and diestrus phases were 
chosen (n = 16 per each group) (Baravalle et al. 2006).
Blood and tissues samples
Collection of blood and tissue samples was performed 
between 1:00 and 3:00 pm during proestrus and diestrus 
stages of the estrous cycle of control rats and from acyclic 
PCOS-induced rats. Animals were deeply anesthetized by 
inhalation of 4% isoflurane in an enclosed vessel. Blood 
was withdrawn through the orbital sinus in a tube and cen-
trifuged at 500 g for 15 min at room temperature. Plasma 
was separated and immediately stored at  – 20 °C for further 
analyses. Ovaries and POAT were excised from all animals. 
Separate ovary and surrounding POAT was snap-frozen in 
liquid nitrogen for RNA and protein isolation, 1,25(OH)2D3 
concentration measurement, as well as was fixed in formalin 
(10% buffered formalin for ovaries and zinc-formalin for 
POAT) for routine histology (hematoxylin–eosin staining) 
and immunohistochemistry.
Antibody validation
Antibody specificity (anti-VDR, anti-CYP27B1 and anti-
CYP24A1) was determined by Western blot analysis per-
formed on lysates from rat kidney (positive control tissue 
for VDR, CYP27B1 and CYP24A1) and rat heart (nega-
tive control tissue for CYP27B1 and CYP24A1) in com-
parison to lysates from rat ovary. Analyzed proteins were 
shown in kidney and ovarian samples as specific bands at 
approximately 48 kDa (VDR), 56 kDa (CYP27B1) and 
59 kDa (CYP24A1) (Supplementary File 1). Furthermore, 
the analysis of non-specific binding of secondary antibod-
ies by omission of primary antibodies was conducted (Sup-
plementary File 2). Validation of primary antibodies was 
also performed by immunohistochemistry on rat kidney sec-
tions as a positive control. The incubation of sections with 
respective non-immune serum (rabbit: NI01 or goat: NI02; 
Calbiochem, Darmstadt, Germany) was used as a negative 
control (Supplementary File 3).
According to policy of antibody validation we applied 
independent antibody strategy with other antibodies against 
VDR (MA1-710; Thermo Scientific, Rockford, IL, USA) 
and CYP27B1 (PA5-79,128; Thermo Fisher Scientific) rec-
ognizing different region of target proteins when compared 
to primary antibodies used in the present study. The expres-
sion pattern generated by two independent antibodies toward 
VDR and CYP27B1 proteins yield correlated signals across 
loading samples, suggesting that both antibodies recognize 
the intended target (Supplementary File 4).
The anti-CYP24A1 antibody used in the present study 
was specific for rat and validated on rat tissues following 
manufacturer’s recommendation. It recognizes 153–514 
amino acids sequence of human CYP24A1, which is homol-
ogous with rat in 86%. Furthermore, the specificity of this 
antibody was confirmed by Western blot and immunohisto-
chemistry as shown in Supplementary Files 1 and 3.
Ovarian and POAT histology
Paraplast-embedded ovaries and POAT from controls and 
letrozole-treated group were cut into 5 µm-thick sections 
and mounted on 3′3′-aminopropyl-triethoxysaline-coated 
(Sigma-Aldrich) slides. After deparaffinization and rehy-
dration, tissue sections were stained with hematoxylin QS 
(Vector Laboratories, Burlingame CA, USA) and eosin Y 
(Sigma-Aldrich). Next, stained slides were dehydrated, 
mounted in DPX (Sigma-Aldrich) and coverslipped. Digi-
tal images were collected using an Axio Scope A1 micro-
scope with EC Epiplan-NEOFLUAR objectives (Carl Zeiss, 
Jena, Germany) equipped with an Axiocam 503 color 
camera (2.83 megapixel: 1936 (H) × 1460 (V); pixel size 
4.54 μm × 4.54 μm) with ZEN 2.3 pro software (Carl Zeiss, 
Jena, Germany).
Periovarian adipocyte size was measured according to 
Benrick et al. (2017). The quantification was conducted 
using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA) and five representative micrographs 
per animal were analyzed. Following transformation to a 
16-bit grayscale and setting the threshold to exclude anoma-
lies such as blood vessels, the micrographs were transformed 
to black-and-white binary images and broken adipocyte 
plasma membranes were mended by applying the watershed 
function. Adipocytes were defined by circularity and cell 
area was measured in relation to a scale bar.
T and  E2 plasma concentration
T and  E2 concentrations were determined in peripheral 
blood plasma using commercially available enzyme-
linked immunosorbent assay kits (DRG MedTek, Warsaw, 
Poland). The sensitivity of each assay was 0.083 ng/mL for 
T and 9.714 pg/mL for  E2, with ranges of 0–16 ng/mL, and 
0–2000 pg/mL, respectively. The intra- and inter-assay coef-
ficients of variation for T were 3.28% and 6.71%, respec-
tively, and those for  E2 were 2.71% and 6.72% respectively. 
All analyses were performed in duplicate.
Calcium plasma concentration
Plasma calcium concentration was measured using com-
mercial colorimetric assays (Pointe Scientific, Brussels, Bel-
gium) according to the manufacturer’s protocol. Detection 
limit was 1 mg/dL. The intra- and inter-assay coefficients 
of variation were 1.1% and 2.0%, respectively. All analyses 
were performed in duplicate.
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25OHD plasma concentration
The concentration of total 25OHD  (25OHD3 and  25OHD2) 
in peripheral blood plasma was determined using a radio-
immunological commercial kit (25OH-Vitamin D total-
RIA-CT; DIAsourceImmunoAssays, Louvain-la-Neuve, 
Belgium), following the manufacturer’s instruction. The 
concentration of 25OHD was measured using 125I-labeled 
hormone, standards and test tubes coated with an appro-
priate monoclonal antibody. Assay limit of detection was 
5.67 pg/mL and the intra- and inter-assay coefficients of 
variation were 5.9% and 7.4%, respectively. All analyses 
were performed in duplicate.
1,25(OH)2D3 concentration in ovarian tissue 
and POAT
The concentration of 1,25(OH)2D3 in homogenates of ova-
ries and POAT was determined using a radioimmunological 
commercial kit (1,25(OH)2-Vitamin D-RIA-CT; DIAsour-
ceImmunoAssays, Louvain-la-Neuve, Belgium). Prior to 
radioimmunoassay, fragments of ovaries and POAT from 
controls as well as letrozole-treated rats were weighed, 
homogenized in liquid nitrogen and dissolved in 0.1 M phos-
phate buffered saline (w/v) (PBS; pH 7.4). Following the 
manufacturer’s protocol, the concentration of 1,25(OH)2D3 
was measured using 125I-labeled hormone, standards and 
test tubes coated with an appropriate antibody. Assay limit 
of detection was 2.88 pg/mL and the intra- and inter-assay 
coefficients of variation were 7.4% and 11.3%, respectively. 
1,25(OH)2D3 concentration in ovaries and POAT was 
expressed as ng per mg of examined tissue. All analyses 
were performed in duplicate.
Quantitative real‑time PCR analysis
Total cellular RNA was extracted from frozen ovarian and 
POAT samples using TRI Reagent solution (Ambion, Aus-
tin, TX, USA) according to the manufacturer’s protocol. The 
quality and quantity of RNA were evaluated by measuring 
A260/A280 ratio using a NanoDrop™Lite Spectropho-
tometer (Thermo Scientific, Wilmington, DE, USA). Total 
RNA (1 µg) was used as a template in cDNA synthesis with 
High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). The resulting cDNA 
was used for quantitative PCR using TaqMan Gene Expres-
sion Master Mix (Applied Biosystems) and rat-specific 
TaqMan Gene Expression Assays (Applied Biosystems) 
for Vdr (Rn00690616_m1), Cyp27b1 (Rn00587137_m1) 
and Cyp24a1 (Rn01423143_m1) following manufacturers’ 
instructions. Real-time PCR reactions were conducted in 
duplicate with StepOne™ Real-Time PCR System (Applied 
Biosystems) according to the recommended cycling program 
(2 min at 50 °C, 10 min at 95 °C, 40 cycles of 15  s at 
95 °C, and 1 min at 60 °C). Amplification of contaminat-
ing genomic DNA was checked by control experiments in 
which reverse transcriptase was omitted during the reverse 
transcription step. Relative mRNA quantification data were 
analyzed using the real-time PCR Miner algorithm (Zhao 
and Fernald 2005). The real-time PCR data obtained for Vdr, 
Cyp27b1 and Cyp24a1 were normalized to endogenous con-
trol, glyceraldehyde-3-phosphate dehydrogenase (Gapdh; 
assay ID: Rn01775763_g1).
Western blot analysis
Extraction and quantification of proteins as well as West-
ern blot analysis were performed as described previously 
(Rak-Mardyła et al. 2013). Proteins (50 μg/mL) were recon-
stituted directly in appropriate amounts of sample buffer, 
separated by12% SDS-PAGE using Mini-Protean TGX Sys-
tem Precast Protein Gels (Bio-Rad, Hercules, CA, USA) and 
then transferred to Trans-Blot Turbo Mini PVDF Transfer 
membranes (Bio-Rad). The membranes were washed and 
blocked in 0.02 M Tris-buffered saline containing 5% (w/v) 
bovine serum albumin (BSA) and 0.1% (v/v) Tween 20 and 
incubated overnight at 4 °C with primary antibodies: rabbit 
polyclonal anti-VDR (dilution 1:1000; cat. no 12550, Cell 
Signaling Technology, Danvers, MA, USA), goat polyclonal 
anti-CYP27B1 (dilution 1:200; cat. no sc-49643, Santa Cruz 
Biotechnology, Dallas, TX, USA), rabbit polyclonal anti-
CYP24A1 (dilution 1: 1000: cat. no PA5-79,127, Thermo 
Fisher Scientific). Next, the membranes were washed with 
TBS (Tris-buffered saline) containing 0.1% (v/v) Tween 
20 and incubated for 1 h with secondary horseradish per-
oxidase-conjugated goat anti-rabbit (dilution 1:1000; Cell 
Signaling Technology) or donkey anti-goat (dilution 1:1000; 
Santa Cruz Biotechnology) antibodies. Each membrane was 
stripped and reprobed with monoclonal mouse anti-β-actin 
antibody (1: 5000; Sigma-Aldrich) followed by horseradish 
peroxidase-conjugated horse anti-mouse antibody (dilution 
1:1000; Cell Signaling Technology). Signals were detected 
by chemiluminescence using WesternBright Quantum 
(Advansta Inc., Menlo Park, CA, USA) and visualized using 
the Chemidoc XRS + System (Bio-Rad). All visible bands 
were densitometrically quantified and normalized to their 
corresponding β -actin bands using ImageJ software with 
the “Gel Analysis” functions. Semi-quantitative analysis was 
performed for three separately repeated experiments.
Immunohistochemistry
Immunohistochemistry was performed as previously 
described (Szołtys et al. 2010; Grzesiak et al. 2019). Briefly, 
sections were deparaffinized, rehydrated and subjected to 
microwave (750 W) antigen retrieval in 0.01 M (w/v) citrate 
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buffer (pH 6.0) for 12 min. Endogenous peroxidase activity 
was blocked with 0.3% (v/v)  H2O2 in TBS for 20 min. To 
block non-specific binding sites, sections were incubated in 
5% (v/v) normal rabbit or goat serum in TBS for 40 min. 
Sections were then incubated overnight with primary anti-
bodies (for specification see "Western blot analysis") as 
follows: anti-VDR (dilution 1:50), anti-CYP27B1 (dilution 
1:50) and anti-CYP24A1 (dilution 1:300). Next, slides were 
incubated with secondary biotinylated goat anti-rabbit (dilu-
tion 1:300; Vector Laboratory, Burlingame, CA, USA) or 
horse anti-goat (1:300; Vector Laboratory) antibodies for 
1.5 h at room temperature, and avidin–biotin-peroxidase 
complex (Vectastain Elite ABC Reagent, Vector Laborato-
ries) for 40 min at room temperature. Bound antibody was 
visualized with TBS containing 0.01% (v/v)  H2O2, 0.05% 
(w/v) 3,3′-diaminobenzidine (DAB; Sigma-Aldrich) and 
0.07% (w/v) imidazole for 1 min. Negative controls were 
performed by substituting the primary antibody with non-
immune rabbit (NI01; Calbiochem) or goat (NI02; Calbio-
chem) IgGs. Sections were dehydrated, cleared in xylene 
and mounted in DPX (Sigma-Aldrich). Selected slides were 
photographed using an Axio Scope A1 microscope and an 
Axiocam503 color camera with ZEN 2.3 pro software.
Statistical analysis
Statistical analyses were performed using Statistica v.13.1 
software (StatSoft, Inc, Tulsa, OK, USA). All data are pre-
sented as the overall mean ± standard error of the mean 
(SEM), and differences were considered statistically sig-
nificant at the 95% confidence level.
(P < 0.05). To verify the normal distribution of data the 
Shapiro–Wilk and the Lilliefors tests were applied. Data 
on T and  E2, 25OHD, 1,25(OH)2D3 and calcium concen-
trations were analyzed by one-way ANOVA followed by 
Tukey post hoc test; BW results were analyzed by Student’s 
t test. Data from real-time PCR and Western blot analyses 
showed a lack of normal distribution and so the nonpara-
metric Kruskal–Wallis test was applied and the differences 
between individual groups determined by post hoc Dunn’s 
multiple comparison test.
Results
Effect of letrozole administration on rat BW
Letrozole-treated rats gained more weight than controls 
(Fig. 1). Statistically significant differences in BW between 
control and letrozole-treated rats appeared from day 7 
(p < 0.05) and gradually increased over the course of the 
experiment (p < 0.001).
Effect of letrozole administration on steroid 
concentrations
Plasma T concentration significantly increased (p < 0.05) in 
letrozole-treated rats when compared to both control groups 
(Fig. 2a). Plasma  E2 concentration markedly decreased 
(p < 0.05) following letrozole administration in comparison 
to the proestrus control group, and was similar to that in 
diestrus control rats (Fig. 2b).
Fig. 1  Daily changes in body weight during the course of experiment in control (n = 16) and letrozole-treated (n = 8) rats. Values are expressed 
as mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test)
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Effect of letrozole administration on estrous 
cyclicity and ovarian histology
Animals in both control groups had normal estrous cycle, 
while rats treated with letrozole were acyclic. Control rats 
in proestrus (Fig. 3a) and diestrus (Fig. 3b) displayed nor-
mal follicular development (preantral follicles, antral fol-
licles and corpora lutea), whereas letrozole administration 
resulted in ovarian cysts and anovulation confirmed by the 
lack of corpora lutea (Fig. 3c).
Fig. 2  Plasma concentrations of testosterone and 17β-estradiol in 
control (proestrus and diestrus; n = 8 per each group) and letrozole-
treated (n = 8) rats. Values are expressed as mean ± SEM. Different 
letters denote statistically significant differences (p < 0.05; one-way 
ANOVA followed by Tukey post hoc test)
Fig. 3  Histology of ovaries obtained from control (a—proestrus and b – diestrus; n = 3 per each group) and letrozole-treated (c; n = 3) rats. Af 
antral follicle, CL corpus luteum, asterisks – ovarian cysts; arrows – preantral follicle. Scale bars represent 200 µm
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Effect of letrozole administration on adipocyte size 
in POAT
The average size of adipocytes in POAT was greatest in 
proestrus control rats (p < 0.001; Fig. 4a, d), less in the letro-
zole-treated group (p < 0.05; Fig. 4c, d) and least in diestrus 
control rats (p < 0.05; Fig. 4b, d).
Effect of letrozole administration on plasma 25OHD 
and calcium concentrations, and 1,25(OH)2D3 tissue 
concentration
Plasma 25OHD concentration decreased markedly (p < 0.05; 
Fig. 5a) in the group treated with letrozole in comparison to 
both control groups, whereas calcium concentration did not 
vary between the groups (p < 0.05; Fig. 5b). Neither 25OHD 
nor calcium level differed between proestrus and diestrus 
phases (Fig. 5a, b).
The 1,25(OH)2D3 concentration in homogenates of ovar-
ian tissue (p < 0.01; Fig. 5c) and POAT (p < 0.05; Fig. 5d) 
was lower in the letrozole-treated group than in both proes-
trus and diestrus controls.
Effect of letrozole administration on Vdr, Cyp27b1 
and Cyp24a1 mRNA expression in the ovary 
and POAT
The expression of ovarian Vdr mRNA was greater in rats 
treated with letrozole and control rats in diestrus than in the 
proestrus control group (p < 0.05; Fig. 6a). Cyp27b1 mRNA 
expression was lower in the ovaries of the letrozole-treated 
group and diestrus control group when compared with con-
trol rats in proestrus (p < 0.05; Fig. 6b), whereas the expres-
sion of Cyp24a1 mRNA was unchanged (Fig. 6c).
In POAT, only Cyp27b1 mRNA expression markedly 
decreased following letrozole administration in comparison 
with both control groups (p < 0.05; Fig. 6e), while expres-
sion of Vdr (Fig. 6d) and Cyp24a1 (Fig. 6f) mRNAs did not 
differ between control and letrozole-treated groups.
Fig. 4  Histology of periovarian adipose tissue obtained from control 
(a proestrus and b – diestrus; n = 4 per each group) and letrozole-
treated (c; n = 4) rats. Chart (d) represents adipocyte size in each 
examined group. Values are expressed as mean ± SEM. Different 
letters denote statistically significant differences (p < 0.05; one-way 
ANOVA followed by Tukey post hoc test). Scale bars represent 50 µm
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Effect of letrozole administration on VDR, CYP27B1 
and CYP24A1 protein abundance in the ovary 
and POAT
In the ovary (Fig. 7a) and POAT (Fig. 7e) of control and letro-
zole-treated rats, analyzed proteins were shown as bands at 
approximately 48 kDa (VDR), 56 kDa (CYP27B1) and 59 kDa 
(CYP24A1).
The ovarian VDR protein abundance significantly increased 
(p < 0.05; Fig.  7b), while CYP27B1 protein markedly 
decreased (p < 0.05; Fig. 7c) following letrozole administra-
tion when compared to both control groups. CYP24A1 protein 
abundance was at the same level in letrozole-treated rats and 
controls (Fig. 7d).
In POAT, diminished abundance of CYP27B1 protein was 
only observed in rats treated with letrozole (p < 0.05; Fig. 7g), 
while VDR (Fig. 7f) and CYP24A1 (Fig. 7h) protein abun-
dances were unchanged between letrozole-treated and control 
groups.
Immunolocalization of VDR, CYP27B1 and CYP24A1 
in the ovary and POAT
Positive nuclear VDR staining was found in both ovarian 
(Fig. 8) and POAT (Fig. 9) sections from the letrozole-
treated group (Figs. 8c and 9c) as well as control in proestrus 
(Fig. 8a and Fig. 9a) and diestrus (Figs. 8b and 9b). In the 
control ovaries (Fig. 8a, b), VDR immunoreaction was found 
in granulosa and theca cells of preantral and antral ovarian 
follicles, and in luteal cells of corpora lutea. In the letrozole-
treated group (Fig. 8c), VDR was detected in cells within 
the luteinized wall of follicular cysts. In POAT, VDR was 
observed in the nuclei of adipocytes in all studied groups 
(Fig. 9a–c).
Both metabolizing enzymes, CYP27B1 and CYP24A1, 
displayed cytoplasmic localization in ovarian (Fig. 8) and 
POAT (Fig. 9) sections. In the ovary, CYP27B1 (Fig. d-f) 
and CYP24A1 (Fig. 8g–i) were found exclusively in the 
granulosa cells of healthy follicles with a lack of positive 
Fig. 5  Plasma concentrations of 25OHD (a) and calcium (b), and 
1,25(OH)2D3 in homogenates of ovaries (c) and periovarian adipose 
tissue (POAT; d) in control (proestrus and diestrus; n = 8 per each 
group) and letrozole-treated (n = 8) rats. Values are expressed as 
mean ± SEM. Different letters denote statistically significant differ-
ences (p < 0.05; one-way ANOVA followed by Tukey post hoc test)
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staining in follicular cysts (Fig. 8f, i). CYP27B1 (Fig. 9d–f) 
and CYP24A1 (Fig. g–i) were positively localized in the 
cytoplasm of adipocytes in all examined groups. Either in 
ovaries (Fig. 8) or POAT (Fig. 9), CYP24A1 immunostain-
ing was weaker than CYP27B1 immunoreaction.
Discussion
Recently a growing body of evidence highlights that  VD3 
plays an important role in the ovary and its deficiency is 
linked with several ovarian pathologies such as PCOS. 
Keeping in mind the expression of CYP27B1 responsible 
for active  VD3 synthesis and VDR in ovarian tissue, the 
question arises whether  VD3 metabolism at the ovarian 
level is disrupted in PCOS. Therefore, the present study 
has been undertaken to examine the local  VD3 metabolism 
and the expression of  VD3-related molecules (VDR, 
CYP27B1 and CYP24A1) in ovarian tissue and POAT 
of control rats (at proestrus and diestrus) and those with 
PCOS induced by the aromatase inhibitor letrozole.
Herein, letrozole-treated rats exhibited key PCOS traits, 
including acyclicity, anovulation confirmed by the lack of 
corpora lutea, cystic ovarian morphology and increased 
BW that is in agreement with previous observations on 
rodents exposed to letrozole (Kafali et al. 2004; Bara-
valle et al. 2006; Mannerås et al. 2007; Caldwell et al. 
2014). Furthermore, administration of letrozole led to the 
expected increase in T and decrease in  E2 concentrations 
in plasma, reflecting the blockage of androgen conversion 
to estrogen (Baravalle et al. 2006; Mannerås et al. 2007). 
Thus, the aforementioned results indicate the successful 
induction of PCOS rat model in the current study.
Fig. 6  Relative expression of Vdr (a, d), Cyp27b1 (b, e) and Cyp24a1 
(c, f) mRNAs in ovaries (a–c) and periovarian adipose tissue (d–f) 
obtained from control (proestrus and diestrus; n = 8 per each group) 
and letrozole-treated (n = 8) rats. The mRNA expression was deter-
mined using quantitative real-time PCR and presented relative to 
Gapdh as mean ± SEM. Different letters denote statistically signifi-
cant differences (p < 0.05; Kruskal–Wallis test followed by post hoc 
Dunn’s multiple comparison test)
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Fig. 7  Relative abundance of VDR (b, f), CYP27B1 (c, g) and 
CYP24A1 (d, h) proteins in ovaries (b–d) and periovarian adipose 
tissue (POAT; f–h) obtained from control (proestrus and diestrus; 
n = 8 per each group) and letrozole-treated (n = 8) rats. Each protein 
abundance was evaluated densitometrically and expressed as the 
ratio relative to β-actin (ACTB) abundance (mean ± SEM). The frag-
ment of membrane with bands corresponding to predicted molecular 
weights are shown (a—ovary; e— POAT). Different letters denote 
statistically significant differences (p < 0.05; Kruskal–Wallis test fol-
lowed by post hoc Dunn’s multiple comparison test)
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It is proposed that  VD3 deficiency correlates with the 
occurrence of PCOS. Based on epidemiologic studies, its 
prevalence in PCOS women is approximately 67–85% (He 
et al. 2015). In accordance with those results, in PCOS rats 
we observed decreased concentration of plasma 25OHD. 
Although lower  VD3 level is common among PCOS patients, 
previous research reported a lack of statistically significant 
differences in  VD3 status between PCOS and non-PCOS 
Fig. 8  Representative micrographs of immunohistochemical VDR, 
CYP27B1 and CYP24A1 localization in ovaries obtained from con-
trol (a, d, g—proestrus and b, e, h—diestrus; n = 3 per each group) 
and letrozole-treated (c, f, i; n = 3) rats. VDR expressed nuclear pat-
tern of staining (a–c), while CYP27B1 (d–f) and CYP24A1 (g–i) 
were observed in the cell cytoplasm. Control sections showed no 
positive staining (b inset, d inset, h inset). CL – corpus luteum; open 
arrow – granulosa cells; black arrows – theca cells; white arrows – 
luteal cells; asterisks – ovarian cysts. Scale bars represent 100 µm
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women (Moini et al. 2015). It is noteworthy that a mark-
edly diminished 25OHD level was found in obese compared 
with lean PCOS patients, suggesting that hypovitaminosis 
 D3 results from obesity but is independent of the presence of 
PCOS (Yildizhan et al. 2009). In this context, the increased 
BW of letrozole-treated rats observed here might be related 
to their diminished plasma 25OHD level. It is known that 
abdominal obesity contributes to the development of insu-
lin resistance in PCOS women, and a positive association 
between  VD3 deficiency and this metabolic disorder was 
also indicated (Yildizhan et al. 2009; He et al. 2015).  VD3 
was shown to enhance insulin synthesis and release, increase 
insulin receptor expression and inhibit the production of pro-
inflammatory cytokines that might counteract the develop-
ment of insulin resistance (Sung et al. 2012). In turn, insulin 
increases ovarian androgen synthesis aggravating hyperan-
drogenism (Sam and Dunaif 2003). Thus,  VD3 deficiency 
might play vital role in the development of subsequent meta-
bolic and endocrine disorders in PCOS.
It is thought that  VD3 deficiency in PCOS affects calcium 
homeostasis, resulting in inhibition of oocyte resumption 
and follicular arrest (Thys-Jacobs et al. 1999). To support 
this hypothesis, several reports indicated positive effects of 
 VD3 and calcium supplementation on menstrual irregular-
ity and infertility in PCOS patients with low  VD3 status 
(Thys-Jacobs et al. 1999; Firouzabadi et al. 2012; Kadoura 
et al. 2019). On the other hand, there were no differences 
in calcium level between control and PCOS women (Thys-
Jacobs et al. 1999; Moini et al. 2015). In agreement with 
those findings, we have observed no significant changes in 
plasma calcium concentrations between PCOS rats and con-
trol groups. Thys-Jacobs et al. (1999) indicated that calcium 
metabolism was disrupted in PCOS patients with  VD3 defi-
ciency and hyperparathyroidism despite normal extracellular 
calcium concentration. They suggested that dysregulation in 
intracellular calcium signaling might affect oocyte develop-
ment and ovulation. However, further studies are needed to 
confirm this.
Recent studies on humans (Masjedi et al. 2020) and on 
a PCOS mouse model (Bakhshalizadeh et al. 2017, 2018) 
have reported improved steroidogenesis and enzymatic 
antioxidant defense in the granulosa cells isolated from 
Fig. 9  Representative micrographs of immunohistochemical VDR, 
CYP27B1 and CYP24A1 localization in periovarian adipose tissue 
obtained from control (a, d, g—proestrus and b, e, h—diestrus; n = 3 
per each group) and letrozole-treated (c, f, i; n = 3) rats. VDR was 
observed in the nuclei of adipocytes (a–c; arrows), while CYP27B1 
(d–f; arrows) and CYP24A1 (g–i; arrows) were found in adipocytes 
cytoplasm. Scale bars represent 50 µm
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polycystic ovaries following  VD3 treatment. This sug-
gests a critical role of  VD3 in establishing proper follicu-
lar function in PCOS and that an altered  VD3 metabolic 
homeostasis is possible in polycystic ovaries. Disturbed 
 VD3 metabolism has been demonstrated in reproductive 
disorders such as endometriosis (Viganò et  al. 2006), 
preeclampsia (Ma et  al. 2012) and ovarian carcinoma 
(Brożyna et al. 2015), but not in PCOS. The present study 
shows for the first time a significant reduction of intrao-
varian 1,25(OH)2D3 concentration in letrozole-treated rats 
when compared with controls in proestrus and diestrus. 
That is probably due to diminished ovarian expression of 
CYP27B1, which is responsible for the synthesis of active 
 VD3, at mRNA and corresponding protein levels in that 
group. Furthermore, positive CYP27B1 immunostaining 
was found only in the granulosa cells of healthy follicles, 
but not in cystic ones. Besides indicating that the rat PCOS 
ovary is a site of local  VD3 synthesis, we have now demon-
strated its capacity for 1,25(OH)2D3 catabolism by reveal-
ing CYP24A1 expression and immunolocalization. In the 
ovary of PCOS-induced rats, the expression of mRNA 
and abundance of protein for CYP24A1 were unchanged. 
Therefore, our results demonstrate that ovarian conver-
sion of the circulating  25OHD3 to active 1,25(OH)2D3 is 
decreased in PCOS rat model, and this may contribute to 
 VD3 deficiency observed in PCOS.
It is well known that  VD3 regulates ovarian function 
through its cognate receptor VDR, expressed abundantly in 
the mammalian ovary (Herian et al. 2018; Xu et al. 2018). 
The present immunohistochemical results demonstrate 
VDR distribution in granulosa and theca cells of healthy 
rat ovarian follicles, consistent with Johnson et al. (1996). 
In addition, VDR was detected in the luteinized wall of the 
follicular cysts. Vdr mRNA expression was greater in the 
ovary of letrozole-treated rats and control rats in diestrus 
than in proestrus control, whereas VDR protein abundance 
was increased only in the PCOS group. VDR gene is known 
to be up-regulated by various hormones including parathor-
mone, retinoic acid, glucocorticoids and calcitriol due to 
their action in the VDR promoter region (Pike and Meyer 
2010). There are also studies on human ovarian cancer 
cells (Ahonen et al. 2000) and breast cancer cells (Escaleira 
et al. 1993) indicating increased VDR protein abundance 
in response to dihydrotestosterone in vitro. Based on these 
results, a similar mechanism might exist in PCOS under 
hyperandrogenic conditions, explaining the increased ovar-
ian VDR protein level following letrozole treatment seen 
here. Furthermore, androgens were shown to regulate VDR 
signal transduction through suppression of VDR/retinoid 
X receptor (RXR) dimerization in porcine ovarian follicles 
(Herian et al. 2018). Thus, the altered response of ovarian 
cells to  VD3 in PCOS, independently of the VDR protein 
level, cannot be excluded.
Recent research clearly demonstrates that white adipose 
tissue surrounding the ovaries controls ovarian function 
through paracrine interactions (Yang et al. 2018). In POAT-
deficient mice, the overall estrogens and gonadotropin lev-
els were altered with consequent disturbance to the estrous 
cycle (Wang et al. 2017). Furthermore, removal of POAT 
resulted in delayed antral follicle development, increased 
number of atretic follicles, decreased intraovarian steroi-
dogenic enzyme expression and lipid accumulation, which 
might reduce the availability of substrate for local steroid 
production (Yang et al. 2018). Adipose tissue is well known 
as a large endocrine tissue that can also store and metabolize 
 VD3 (Abbas 2017). However, information on  VD3 metabo-
lism in gonadal adipose tissue is scarce. Recent data showed 
hypertrophied adipocytes and enhanced inflammation in 
POAT under dietary restriction of  VD3 in a mouse model of 
menopause (Borges et al. 2020), indicating a link between 
 VD3 deficiency and POAT function. Considering the role 
of POAT in ovarian processes, its endocrine function and 
the occurrence of hypovitaminosis  D3 in PCOS women, an 
examination of  VD3 metabolism in gonadal adipose tissue 
around polycystic ovaries appears to be required.
The expression of  VD3-related molecules, including 
CYP27B1 and CYP24A1, and VDR has been previously 
described in adipose tissue (Abbas 2017). However, our 
current research demonstrates for the first time Cyp27b1, 
Cyp24a1 and Vdr mRNA expression as well as CYP27B1, 
CYP24A1 and VDR protein abundance and immunolocal-
ization in rat POAT. In addition, we have found reduced 
1,25(OH)2D3 concentration in POAT obtained from PCOS 
rats in comparison with control groups. Accordingly, rat 
POAT is a local site of  VD3 metabolism. These results are 
consistent with previous studies showing the production 
of active  VD3 by visceral and subcutaneous adipose tis-
sue (Abbas 2017). The diminished amount of 1,25(OH)2D3 
in POAT of letrozole-treated rats was probably due to the 
decreased Cyp27b1 mRNA expression and CYP27B1 pro-
tein abundance observed in this group. Notably, we did 
not find any changes in CYP24A1 and VDR expression at 
mRNA and protein level between studied groups. In adipose 
tissue, CYP27B1 level is lower in obese than lean women, 
whereas CYP24A1 expression does not differ between them 
(Wamberg et al. 2013) explaining obesity associated  VD3 
deficiency. This seems to apply to  VD3 deficiency in PCOS 
accompanied by obesity. It is plausible that obese people 
degrade more  VD3 in their adipose tissue via CYP24A1 
than lean ones. Thus, these data could support the hypoth-
esis of an increased catabolism of VD in obesity besides 
unchanged CYP24A1 expression (Vranić et al. 2019). Obe-
sity results from the increase in adipocyte number and size 
(Abbas 2017). Herein we have noted adipocyte hypertrophy 
in letrozole-treated animals when compared with the con-
trol in diestrus, but not when compared with the proestrus 
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control. There are discrepancies between literature reports 
on the effect of letrozole on adipocyte size in rats. One study 
revealed enlargement (Mannerås et al. 2007), while another 
found no change (Caldwell et al. 2014). It should be stressed 
that neither study was related to POAT.
In conclusion, our results provide novel evidence of dis-
rupted  VD3 metabolism in the ovary and POAT of rats with 
induced PCOS. The reduced 1,25(OH)2D3 concentration in 
those tissues suggests that they contribute to the  VD3 defi-
ciency observed in PCOS and might be implicated in PCOS 
pathogenesis. Furthermore, the letrozole-induced PCOS rat 
model exhibiting decreased 25OHD plasma level may be 
valuable for further studies on the role of  VD3 deficiency in 
this reproductive disorder.
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